Artiva Biotherapeutics Inc. (ARTV) Stock Price, Quote & News

Company Profile

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vascul...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 267 4467

Website: www.artivabio.com

Address:

5505 Morehouse Drive, Suite 100, San Diego, United States

TNNStockAnalysisNews Sep. 4 at 1:00 AM

Stocks to Watch Tomorrow, Sep 4, 2026: $TE — Closed Near $4.51, Pivoting From Solar Into AI Data Centers $ARTV — Trading Near $9.78, a 300%+ Analyst Target Gap $SHIP — A Dry Bulk Shipper Near $18, Up 24.8% in Two Weeks $AGIO — A Hematology Biotech With $52-55 Analyst Targets $SHLS — Solar EBOS Maker Near $7, Guidance Raised https://truthsandnews.com/markets/10-stocks-to-watch-tomorrow-sept-4-2026-small-cap-movers

0 · Reply

Papermoon347 Aug. 28 at 4:17 AM

$ARTV is today the day we close above,12.25 and make a run to 15?

2 · Reply

aletz Aug. 22 at 6:33 AM

$ARTV Latest full conversation with CEO Fred Aslan, must watch for investors. https://youtu.be/I9eCndzNTAI?is=EaPQEMZtEqJq6dh6

0 · Reply

aletz Aug. 7 at 7:46 PM

$NKTX I like a quiet climb here. Phase 1 data imminent and phase 1s have tendency of showing primises and although the science it's not exactly the same but $ARTV has already shown strong potential and hopefully Nkarta can show it can be done without a need of mAbs. Holding both btw.

0 · Reply

dougdchef Aug. 6 at 7:04 PM

$ARTV The earnings report was to have come out yesterday, I believe, but I’ve seen nothing on it. Hummm

1 · Reply

Kikikikiii Aug. 5 at 10:26 PM

$ARTV 20$ end of yesr

1 · Reply

shahid7777 Aug. 5 at 6:24 PM

$ARTV Can you break 12 this week?

0 · Reply

aletz Aug. 4 at 6:45 PM

$ARTV Is RA Capital attempting to acquire all outstanding shares? 😅😅

1 · Reply

aletz Aug. 4 at 6:43 PM

$ARTV Lack of interest on this thread is unbelievable, particularly given Artiva's exceptional performance. We are expecting significant catalysts later this year, including the initiation of Phase 3 trials and forthcoming updates on the durability of their basket study.

0 · Reply

Merlintrader Jul. 30 at 9:03 AM

Artiva Biotherapeutics Stock Hub: $ARTV, AlloNK, FDA RMAT and the Phase 3 Rheumatoid Arthritis Path https://www.merlintrader.com/artiva-biotherapeutics-stock-hub/

0 · Reply

Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in September

2026-08-06T21:30:59.000Z - 4 weeks ago

Artiva Biotherapeutics files $400M mixed securities shelf

2026-08-06T21:10:52.000Z - 4 weeks ago

Artiva Biotherapeutics reports Q2 EPS (63c), consensus (64c)

Aug 6, 2026, 4:05 PM EDT - 4 weeks ago

Artiva Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Aug 6, 2026, 8:00 AM EDT - 4 weeks ago

Artiva Biotherapeutics Registration statement: Registration filing

Aug 6, 2026, 7:00 AM EDT - 4 weeks ago

Artiva Biotherapeutics Quarterly report: Q2 2026

Aug 6, 2026, 7:00 AM EDT - 4 weeks ago

Artiva Biotherapeutics Earnings release: Q2 2026

Aug 3, 2026, 8:00 AM EDT - 4 weeks ago

Artiva Biotherapeutics Proxy statement: Proxy filing

Jul 17, 2026, 7:30 AM EDT - 6 weeks ago

Artiva Biotherapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 30, 2026, 3:30 PM EDT - 2 months ago

Artiva Biotherapeutics Transcript: H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

Jun 23, 2026, 4:05 PM EDT - 2 months ago

Artiva Biotherapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

Jun 8, 2026, 8:15 AM EDT - 2 months ago

Artiva Biotherapeutics Transcript: Status update

Jun 8, 2026, 8:15 AM EDT - 2 months ago

Artiva Biotherapeutics Press release: Status update

2026-06-08T10:40:49.000Z - 2 months ago

Artiva Biotherapeutics highlights AlloNK data presented at EULAR 2026

$Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today$

Jun 8, 2026, 6:30 AM EDT - 2 months ago

Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today

Jun 4, 2026, 9:20 AM EDT - 3 months ago

Artiva Biotherapeutics Transcript: Jefferies Global Healthcare Conference 2026

May 28, 2026, 8:00 AM EDT - 3 months ago

Artiva Biotherapeutics to Participate in the 2026 Jefferies Global Healthcare Conference

May 19, 2026, 4:05 PM EDT - 3 months ago

Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at EULAR 2026 Congress, Including Late-Breaking Oral Presentation Highlighting Clinical Efficacy Comparable to Autologous CAR T-Cell Therapy in Rheumatologic Diseases

May 19, 2026, 8:00 AM EDT - 3 months ago

Artiva Biotherapeutics Appoints Veteran Biotech Executive and Drug Developer Diego Miralles, M.D., as President and Head of Research and Development

2026-05-12T18:55:13.000Z - 3 months ago

Artiva Biotherapeutics price target raised to $41 from $18 at Needham

2026-05-11T17:22:01.000Z - 3 months ago

Artiva Biotherapeutics price target raised to $40 from $23 at Wedbush

2026-05-08T20:22:09.000Z - 3 months ago

Artiva Biotherapeutics price target raised to $35 from $15 at H.C. Wainwright

May 8, 2026, 9:30 AM EDT - 3 months ago

Artiva Biotherapeutics Earnings release: Q1 2026

May 8, 2026, 9:30 AM EDT - 3 months ago

Artiva Biotherapeutics Quarterly report: Q1 2026

2026-05-08T10:59:29.000Z - 3 months ago

Artiva Biotherapeutics reports Q1 EPS (95c), consensus (84c)

May 8, 2026, 6:52 AM EDT - 3 months ago

Artiva Biotherapeutics Announces Pricing of $300 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

2026-05-08T10:51:22.000Z - 3 months ago

Artiva reports data from clinical trials evaluating AlloNK

May 8, 2026, 6:31 AM EDT - 3 months ago

Artiva Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights

May 8, 2026, 6:30 AM EDT - 3 months ago

Artiva Announces Positive Initial Clinical Data with AlloNK® Across Multiple Autoimmune Diseases and FDA Alignment to Initiate Phase 3 Registrational Trial in Rheumatoid Arthritis in 2026

Apr 15, 2026, 2:15 PM EDT - 4 months ago

Artiva Biotherapeutics Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 8, 2026, 8:00 AM EDT - 4 months ago

Artiva Biotherapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference

Mar 10, 2026, 4:05 PM EDT - 5 months ago

Artiva Biotherapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights

Mar 10, 2026, 7:00 AM EDT - 5 months ago

Artiva Biotherapeutics Earnings release: Q4 2025

Mar 10, 2026, 7:00 AM EDT - 5 months ago

Artiva Biotherapeutics Annual report: Q4 2025

Mar 4, 2026, 1:10 PM EST - 6 months ago

Artiva Biotherapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Feb 25, 2026, 8:00 AM EST - 6 months ago

Artiva Biotherapeutics to Participate in the TD Cowen 46th Annual Health Care Conference

2026-02-24T13:23:47.000Z - 6 months ago

Artiva Biotherapeutics appoints Huston as Chief Financial Officer

Feb 24, 2026, 8:00 AM EST - 6 months ago

Artiva Biotherapeutics Announces Appointment of Thad Huston as Chief Financial Officer and Award of Inducement Grant

2026-02-19T13:17:45.000Z - 6 months ago

Artiva Biotherapeutics appoints Sorg to board of directors

Feb 19, 2026, 8:00 AM EST - 6 months ago

Artiva Biotherapeutics Announces Appointment of Elaine Sorg to Board of Directors

Jan 21, 2026, 8:00 AM EST - 7 months ago

Artiva Biotherapeutics Announces Upcoming Presentations at the 2026 Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR® (Tandem Meetings) Highlighting Cost-Effectiveness of AlloNK in a Community Rheumatology Practice and Continued Durability of AlloNK in NHL

Nov 18, 2025, 7:00 AM EST - 9 months ago

Artiva Biotherapeutics Transcript: Jefferies London Healthcare Conference 2025

Nov 12, 2025, 11:30 AM EST - 9 months ago

Artiva Biotherapeutics Transcript: TD Cowen Immunology and Inflammation Summit

Nov 12, 2025, 8:00 AM EST - 9 months ago

Artiva Biotherapeutics Transcript: Study Update

Nov 12, 2025, 8:00 AM EST - 9 months ago

Artiva Biotherapeutics Press release: Study Update

2025-11-12T12:36:40.000Z - 9 months ago

Artiva Biotherapeutics announces safety, translational data from AlloNK

Nov 12, 2025, 7:20 AM EST - 9 months ago

Artiva Biotherapeutics Announces Positive Initial Safety and Translational Data Supporting Deep B-Cell Depletion with AlloNK® in Autoimmune Disease

2025-11-12T12:05:30.000Z - 9 months ago

Artiva Biotherapeutics reports Q3 EPS (88c) vs (92c) last year

Nov 12, 2025, 7:00 AM EST - 9 months ago

Artiva Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Nov 12, 2025, 7:00 AM EST - 9 months ago

Artiva Biotherapeutics Earnings release: Q3 2025

Nov 12, 2025, 7:00 AM EST - 9 months ago

Artiva Biotherapeutics Quarterly report: Q3 2025

Nov 3, 2025, 4:05 PM EST - 10 months ago

Artiva Biotherapeutics to Host Virtual Event Discussing Initial Safety and Translational Data in up to 32 Patients with Autoimmune Disease Treated with AlloNK®

Oct 30, 2025, 4:17 PM EDT - 10 months ago

Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in November

2025-10-17T13:16:24.000Z - 10 months ago

Why Is Artiva Biotherapeutics Stock (ARTV) Up 105% Today?

2025-10-17T12:00:36.000Z - 10 months ago

Artiva Biotherapeutics price target raised to $23 from $18 at Wedbush

$Artiva Biotherapeutics Announces Refractory Rheumatoid Arthritis as Lead Indication, Upcoming Data Releases, and Corporate Update$

Oct 16, 2025, 4:05 PM EDT - 10 months ago

Artiva Biotherapeutics Announces Refractory Rheumatoid Arthritis as Lead Indication, Upcoming Data Releases, and Corporate Update

Sep 3, 2025, 9:45 AM EDT - 1 year ago

Artiva Biotherapeutics Transcript: Cantor Global Healthcare Conference 2025

Aug 25, 2025, 4:05 PM EDT - 1 year ago

Artiva Biotherapeutics to Participate in the Cantor Global Healthcare Conference 2025

2025-08-06T21:21:24.000Z - 1 year ago

Artiva Biotherapeutics files $300M mixed securities shelf

Aug 6, 2025, 4:05 PM EDT - 1 year ago

Artiva Biotherapeutics Reports Second Quarter 2025 Financial Results, Recent Business Highlights

Aug 6, 2025, 9:30 AM EDT - 1 year ago

Artiva Biotherapeutics Quarterly report: Q2 2025

Aug 6, 2025, 9:30 AM EDT - 1 year ago

Artiva Biotherapeutics Earnings release: Q2 2025

Aug 6, 2025, 8:00 AM EDT - 1 year ago

Artiva Biotherapeutics Registration statement: Registration Filing

2025-06-11T10:21:17.000Z - 1 year ago

Artiva Biotherapeutics assumed with a Buy at H.C. Wainwright

Jun 4, 2025, 9:20 AM EDT - 1 year ago

Artiva Biotherapeutics Transcript: Jefferies Global Healthcare Conference 2025

May 28, 2025, 4:05 PM EDT - 1 year ago

Artiva Biotherapeutics to Participate in the Jefferies Global Healthcare Conference

May 13, 2025, 4:05 PM EDT - 1 year ago

Artiva Biotherapeutics Announces Longer-term Phase 1/2 Data Demonstrating Prolonged Durability for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting

May 8, 2025, 8:00 AM EDT - 1 year ago

Artiva Biotherapeutics Reports First Quarter 2025 Financial Results, Recent Business Highlights

May 8, 2025, 7:00 AM EDT - 1 year ago

Artiva Biotherapeutics Quarterly report: Q1 2025

May 8, 2025, 7:00 AM EDT - 1 year ago

Artiva Biotherapeutics Earnings release: Q1 2025

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Artiva Biotherapeutics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Artiva Biotherapeutics Proxy statement: Proxy Filing

Apr 28, 2025, 4:35 PM EDT - 1 year ago

Artiva Biotherapeutics to Present Longer-term Phase 1/2 Data for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting

Apr 8, 2025, 4:05 PM EDT - 1 year ago

Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer

Apr 7, 2025, 11:00 AM EDT - 1 year ago

Artiva Biotherapeutics Transcript: 24th Annual Needham Virtual Healthcare Conference

Mar 31, 2025, 4:05 PM EDT - 1 year ago

Artiva Biotherapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Mar 24, 2025, 4:05 PM EDT - 1 year ago

Artiva Biotherapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights

Mar 24, 2025, 9:00 AM EDT - 1 year ago

Artiva Biotherapeutics Annual report: Q4 2024

Mar 24, 2025, 9:00 AM EDT - 1 year ago

Artiva Biotherapeutics Earnings release: Q4 2024

Mar 5, 2025, 2:30 PM EST - 1 year ago

Artiva Biotherapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 20, 2025, 4:05 PM EST - 1 year ago

Artiva Biotherapeutics to Participate in the TD Cowen 45th Annual Health Care Conference

Jan 29, 2025, 4:05 PM EST - 1 year ago

Artiva Biotherapeutics Expands Board of Directors with Appointment of Dan Baker, M.D.

Nov 20, 2024, 10:30 AM EST - 1 year ago

Artiva Biotherapeutics Transcript: Jefferies London Healthcare Conference 2024

Nov 12, 2024, 4:05 PM EST - 1 year ago

Artiva Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Nov 12, 2024, 4:00 PM EST - 1 year ago

Artiva Biotherapeutics Quarterly report: Q3 2024

Nov 12, 2024, 4:00 PM EST - 1 year ago

Artiva Biotherapeutics Earnings release: Q3 2024

Nov 11, 2024, 4:05 PM EST - 1 year ago

Artiva Biotherapeutics to Participate in the Jefferies London Healthcare Conference

Oct 22, 2024, 4:05 PM EDT - 1 year ago

Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors

Sep 10, 2024, 4:05 PM EDT - 1 year ago

Artiva Biotherapeutics to Participate in the 2024 Cantor Fitzgerald Global Healthcare Conference

Aug 29, 2024, 4:05 PM EDT - 2 years ago

Artiva Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Aug 29, 2024, 7:00 AM EDT - 2 years ago

Artiva Biotherapeutics Quarterly report: Q2 2024

Aug 29, 2024, 7:00 AM EDT - 2 years ago

Artiva Biotherapeutics Earnings release: Q2 2024

Jul 18, 2024, 7:08 PM EDT - 2 years ago

Artiva Biotherapeutics Announces Pricing of Upsized $167.0 Million Initial Public Offering

TNNStockAnalysisNews Sep. 4 at 1:00 AM

0 · Reply

Papermoon347 Aug. 28 at 4:17 AM

$ARTV is today the day we close above,12.25 and make a run to 15?

2 · Reply

aletz Aug. 22 at 6:33 AM

$ARTV Latest full conversation with CEO Fred Aslan, must watch for investors. https://youtu.be/I9eCndzNTAI?is=EaPQEMZtEqJq6dh6

0 · Reply

aletz Aug. 7 at 7:46 PM

0 · Reply

dougdchef Aug. 6 at 7:04 PM

$ARTV The earnings report was to have come out yesterday, I believe, but I’ve seen nothing on it. Hummm

1 · Reply

Kikikikiii Aug. 5 at 10:26 PM

$ARTV 20$ end of yesr

1 · Reply

shahid7777 Aug. 5 at 6:24 PM

$ARTV Can you break 12 this week?

0 · Reply

aletz Aug. 4 at 6:45 PM

$ARTV Is RA Capital attempting to acquire all outstanding shares? 😅😅

1 · Reply

aletz Aug. 4 at 6:43 PM

0 · Reply

Merlintrader Jul. 30 at 9:03 AM

Artiva Biotherapeutics Stock Hub: $ARTV, AlloNK, FDA RMAT and the Phase 3 Rheumatoid Arthritis Path https://www.merlintrader.com/artiva-biotherapeutics-stock-hub/

0 · Reply

G101SPM Jul. 24 at 4:26 PM

#INSIDERS $ARTV 10% owner RA Capital bought 264,586 shares at $9.40 - $10 worth approximately $2.6 mln (transaction dates 7/21-7/23). ENR 10% owner bought 120,000 shares at $19.64 - $21.05 worth approximately $2.4 mln (transaction dates 7/21-7/22). $NPWR 10% owner sold 209,142 shares worth approximately $319K (transaction dates 7/21-7/23).

1 · Reply

SocioCobb Jul. 24 at 11:06 AM

$ARTV Interesting form 4s here. Bully!

1 · Reply

AlertsAndNews Jul. 24 at 2:49 AM

$ARTV another big buy from this director. he's been buying alot since mid June. 4th buy. ARTV Artiva Biotherapeutics: Shah Rajeev M. (Director, 10%+) Buys 264,586 Shares @ Average Price of $9.76 (Form 4)

0 · Reply

FilingTracker Jul. 24 at 1:24 AM

$ARTV Insider purchase: https://filingtracker.ai/filing/1315082/0001231919-26-000791?doc=form4-07242026_010725.xml

0 · Reply

Think_Bigly Jul. 22 at 6:22 PM

$ARTV RA Capital trying to buy every share? Now over 17M.

1 · Reply

Doozio Jul. 22 at 12:21 AM

$ARTV after da final MNDY 🐑 🎁 out of the tightness da huckleberries will be below da $$$$ ENTA 🐒🍌🧠⏰♾️

0 · Reply

yva Jul. 18 at 3:09 PM

$ARTV Google finance says : For Artiva Biotherapeutics Inc (NASDAQ:ARTV), analysts maintain a bullish outlook for the end of 2026, with an average price target of approximately $39.00. Forecasts from major firms range from a low of $23.00 to a high of $41.00. As of July 17, 2026, the stock was trading at $9.76, meaning the consensus target represents a potential upside of nearly 300%.

0 · Reply

Think_Bigly Jul. 17 at 7:26 PM

$ARTV Buyout very probable by EOY.. maybe two buyouts. And you think.. Huh? Their RA trial is a lay up. The 3 ptr will be their 2nd target. Their advantage: Efficacy with virtually no toxicity.

0 · Reply

LewisDaKat Jul. 17 at 2:30 PM

$ARTV Artiva Biotherapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://marketwirenews.com/stock/artv/news/artiva-biotherapeutics-announces-new-employee-induce-6819930485705014.html?utm_source=stocktwits

0 · Reply

yva Jul. 17 at 6:25 AM

$ARTV New to ARTV , never catch a falling knife? Did i? .....bought some at USD 9.22 to start....

1 · Reply

kubota2323 Jul. 15 at 10:22 PM

$ARTV Institutional Ownership Managers Funds RA CAPITAL MANAGEMENT, L.P. 39.86% 5AM Venture Management, LLC 9.52% Venrock Adviser, LLC 6.51% venBio Partners LLC 2.15% FRANKLIN RESOURCES INC 2.11% Revelation Capital Management, LLC 1.21% BlackRock, Inc. 0.86% VANGUARD CAPITAL MANAGEMENT LLC 0.84% WELLINGTON MANAGEMENT GROUP LLP 0.79% Propel Bio Management, LLC 0.59%

0 · Reply

Market Cap	N/A
Revenue (ttm)	33.49M
Net Income (ttm)	-27.70M
EPS (ttm)	N/A
PE Ratio	N/A
Forward PE	N/A
Profit Margin	N/A
Debt to Equity Ratio	N/A

Volume	342,500
Avg Vol	N/A
Day's Range	N/A - N/A
Shares Out	N/A
Stochastic %K	N/A
Beta	N/A
Analysts	Strong Buy
Price Target	N/A